- $22.92m
- $15.43m
- $3.02m
Annual balance sheet for TherapeuticsMD, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 64.9 | 38.1 | 4.33 | 5.06 | 7.48 |
| Net Total Receivables | — | — | 3.09 | 3.56 | 4.2 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 119 | 55.4 | 11.8 | 12.3 | 14.4 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 9.06 | 7.66 | 6.87 | 6.1 | 5.29 |
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 169 | 90.5 | 43.3 | 38.8 | 37.7 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 253 | 46.8 | 6.85 | 5.17 | 4.79 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 263 | 55.3 | 14 | 11.5 | 10.8 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -93.6 | 35.1 | 29.3 | 27.4 | 26.9 |
| Total Liabilities & Shareholders' Equity | 169 | 90.5 | 43.3 | 38.8 | 37.7 |
| Total Common Shares Outstanding |